Symptomatic patients with endoscopicaily verified reflux oesophagitis were randomised to a double blind trial in which they received either omeprazole (20 mg once daily) or cimetidine (400 mg four times daily) for four, and if necessary, eight weeks. In an 'intention to treat' analysis, oesophagitis was found to have healed after four weeks in 77 of 137 (56%) 
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Abstract Symptomatic patients with endoscopicaily verified reflux oesophagitis were randomised to a double blind trial in which they received either omeprazole (20 mg once daily) or cimetidine (400 mg four times daily) for four, and if necessary, eight weeks. In an 'intention to treat' analysis, oesophagitis was found to have healed after four weeks in 77 of 137 (56%) in the omeprazole group and in 34 of 133 (26%) in the cimetidine group (p<0001). By eight weeks these values were 71% and 35% respectively; p<0*001. Histological assessments were available for 73% of the patients. At entry, 63% (66 of 104) in the omeprazole group and 60% (56 of 94) in the cimetidine group (ns) had abnormal histology. After the study, the proportions of patients who initially had had abnormal histology but who then progressed to normal were 67% (44 of 66: omeprazole) and 48% (27 of 56: cimetidine) respectively (p<0001). All patients had reflux symptoms at entry. After four weeks, 46% in the omeprazole group and 22% (p<0001) in the cimetidine group were asymptomatic. Diary cards completed for the first two weeks showed that patients treated with omeprazole experienced fewer reflux symptoms by day and night and used fewer antacids. Omeprazole, 20 mg once a day for four to eight weeks, healed a greater proportion of patients with reflux oesophagitis than cimetidine, [1] [2] [3] [4] [5] [6] Figure 1 , and healing rates analysed by endoscopic grade at entry in Table II . In the omeprazole group, healing rates were consistent after four weeks, irrespective of endoscopic grade at entry (r=-0 65; ns), while in the cimetidine group, there was a significant inverse correlation between endoscopic grade at randomisation and healing rates (r= -099; p= 0 00 1). The same pattern was seen after eight weeks (omeprazole, r=-0-28, ns; cimetidine, r=-0-98, p<0 02). A further analysis was carried out to examine whether healing rates were related to the linear extent of the oesophagitis at endoscopy: the reported lengths affected were grouped as -4, 5-9, and 10 cm. At four weeks, the healing rates in the omeprazole group were 59%, 56%, and 45% and in the cimetidine group 29%, 23%, and 17%. At the end of the study, the figures were 75%, 70%, and 54% (omeprazole) and 37%, 36%, and 17% (cimetidine). Healing rates for both the omeprazole and cimetidine groups were significantly negatively correlated with the linear extent of the oesophagitis (all p<0 001). The differences between healing rates in the omeprazole and cimetidine treated groups were statistically significant (p-0 001) except for the ¢10 cm groups in which the numbers of patients were too small for detection of any difference (n= 11 and 12 respectively: Table I) .
A second analysis, including only those patients known to have complied with the protocol, produced equivalent results. At four weeks 55 of 95 (58%) patients on omeprazole and 23 of 84 (27%; p<0 001) patients on cimetidine had healed oesophagitis; after eight weeks, the figures were 78% and 44% (p<0 001). The therapeutic gain for omeprazole over cimetidine was 31% (CI 16 to 45%) at four weeks and 34% (CI 20 to 48%) at eight weeks. The main reasons for excluding patients from this analysis were late attendance for endoscopy (20 patients), the return of tablets and capsules indicating that less than 75% of the prescribed trial medication had been taken (31 patients), or the use of antisecretory drugs in the seven days before randomisation (17 patients).
Too few patients (Table I ) had Barrett's oesophagus for a useful subgroup analysis to be carried out. In three of 10 patients in the omeprazole group and one of four in the cimetidine group, Barrett's oesophagus was recorded at the start of the study but not at the end. 104 (63%) of these patients who received omeprazole had abnormal oesophageal histoiogy (grade 1 and above). In the cimetidine group, the proportion was 56 of 94 (60%). At entry, histological and endoscopic grades were significantly correlated (r=0-26; p<0 001).
After treatment, 33% (22 of 66) of those receiving omeprazole continued to have abnormal histology compared with 52% (29 of 56) of those receiving cimetidine (p<0Q001).
HEALING: MULTIVARIATE ANALYSIS
There was no evidence that age, smoking, alcohol consumption, or hiatus hernia predicted healing. Treatment (omeprazole favouring healing over cimetidine) was the only significant predictor of healing at both four and eight weeks (p<0-001). Histology grade at entry predicted healing at four weeks (p=0037) and the endoscopy grade at entry predicted healing at eight weeks (p=0 05).
SYMPTOMS AT CLINIC VISITS
All patients had symptoms at entry but after four weeks, 46% of those receiving omeprazole compared with 22% on cimetidine were asymptomatic (p<0001). By the end of the trial, these figures had risen to 66% and 41% respectively (p<0-001). The most common single symptom was heartburn, but there was no correlation between the severity of heartburn with either endoscopic grading (r=0-04; p=0Q49) or histological grading (r=0-02; p=076) at entry. Heartburn resolved in a significantly greater proportion of patients receiving omeprazole than cimetidine by four and eight weeks (p<0-001, (Fig 2) ). Regurgitation was reported by 78% in the omeprazole group and 77% in the cimetidine group at entry but after four weeks' treatment, these figures had fallen to 30% and 48% respectively (p<0 01).
OVERALL OUTCOME: ALL CLINICAL ASSESSMENTS Endoscopy and symptoms. After four weeks, 50 (38%) patients in the omeprazole group compared with 15 (12%) in the cimetidine group (p<0O001) were both asymptomatic and had healed oesophagitis as assessed by endoscopy. A further 27 (2 1%) in the omeprazole group and 19 (16%) in the cimetidine group had healed oesophagitis but residual symptoms, and 10 (8%) and 12 (10%) patients respectively had relief of symptoms but still had oesophagitis. Forty four patients (34%) on omeprazole and 75 (62%) on cimetidine were neither healed nor had relief of symptoms. Endoscopy, histology and symptoms. In a subgroup of 170 patients (93 in the omeprazole and 77 in the cimetidine group), all three types of assessment were complete at entry and at the end of the study. Of these, 42 (45%) in the omeprazole group were healed endoscopically and histologically and were asymptomatic, a significantly greater proportion than in the cimetidine group (17 (22%) patients: p<0-01).
DIARY CARDS
Diary card data were analysed for days two to 14 inclusive. Data were available for 84% (omeprazole group) and 81% (cimetidine group) of randomised patients. Results are shown in Figures 3, 4 omeprazole group, healing, assessed endoscopically, occurred at roughly the same rate irrespective of severity at entry, whereas with cimetidine, the healing rates for patients with more than mild oesophagitis were low (Table II) . Moreover, there were only small increases in the healing rates when the duration of treatment with cimetidine 1-6 g/day was increased from four to eight weeks: the therapeutic gain for omeprazole over cimetidine showed no sign of decreasing after eight weeks (31% at four weeks, 36% at eight weeks). Healing rates were correlated with the linear extent of the oesophagitis at entry -the healing rate for cimetidine in extensive oesophagitis (¢ 10 cm) was 17% at the end of the study and that for omeprazole was 54%. A measurement of the linear extent of oesophagitis may be complementary to the more conventional endoscopic grading of severity in comparing drug effects.5
More rapid healing of the lesion, assessed endoscopically or histologically, is not the sole criterion for success of treatment. The speed of relief of symptoms is important for the patient and cannot be assessed solely at monthly clinic visits.
Diary cards have previously been shown to be a sensitive way of detecting differences in the speed of ulcer healing between omeprazole and H2 receptor antagonists.8 In this study, the differences were even more noticeable than in peptic ulcer disease: differences in symptom relief and antacid consumption became apparent after the first three days of treatment.
Both 24 hour oesophageal acid exposure9 and clinical dose finding'" studies indicate that 20 mg once daily omeprazole is appropriate for the treatment of reflux oesophagitis. Where the oesophagitis remains unhealed after longterm, full dose H2 receptor antagonist treatment, 40 mg omeprazole daily is more effective than high dose ranitidine." The present study shows that a dose of 20 mg/day omeprazole is more effective by symptomatic, endoscopic, and histological assessment than 1-6 g/day cimetidine in treating reflux oesophagitis, and that omeprazole heals oesophagitis irrespective of the severity of the disease.
